You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Plasma 25‐hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case–control study
|
|---|---|
| Published in |
International Journal of Cancer, April 2013
|
| DOI | 10.1002/ijc.28172 |
| Pubmed ID | |
| Authors |
Tilman Kühn, Rudolf Kaaks, Susen Becker, Piia‐Piret Eomois, Françoise Clavel‐Chapelon, Marina Kvaskoff, Laure Dossus, Anne Tjønneland, Anja Olsen, Kim Overvad, Jenny Chang‐Claude, Annekatrin Lukanova, Brian Buijsse, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Christina Bamia, Giovanna Masala, Vittorio Krogh, Carlotta Sacerdote, Rosario Tumino, Amalia Mattiello, Genevieve Buckland, María‐José Sánchez, Virginia Menéndez, María‐Dolores Chirlaque, Aurelio Barricarte, H. Bas Bueno‐de‐Mesquita, Fränzel J.B. van Duijnhoven, Carla H. van Gils, Marije F. Bakker, Elisabete Weiderpass, Guri Skeie, Magritt Brustad, Anne Andersson, Malin Sund, Nick Wareham, Kay Tee Khaw, Ruth C. Travis, Julie A. Schmidt, Sabina Rinaldi, Isabelle Romieu, Valentina Gallo, Neil Murphy, Elio Riboli, Jakob Linseisen |
| Abstract |
Experimental evidence suggests that vitamin D might play a role in the development of breast cancer. Although the results of case-control studies indicate that circulating 25-hydroxyvitamin D [25(OH)D] is inversely associated with the risk of breast cancer, the results of prospective studies are inconsistent. A case-control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out comprising 1,391 incident breast cancer cases and 1,391 controls. Multivariable conditional logistic regression models did not reveal a significant overall association between season-standardized 25(OH)D levels and the risk of breast cancer (ORQ4-Q1 [95% CI]: 1.07 [0.85-1.36], ptrend = 0.67). Moreover, 25(OH)D levels were not related to the risks of estrogen receptor positive tumors (ORQ4-Q1 [95% CI]: 0.97 [0.67-1.38], ptrend = 0.90) and estrogen receptor negative tumors (ORQ4-Q1 [95% CI]: 0.97 [0.66-1.42], ptrend = 0.98). In hormone replacement therapy (HRT) users, 25(OH)D was significantly inversely associated with incident breast cancer (ORlog2 [95% CI]: 0.62 [0.42-0.90], p = 0.01), whereas no significant association was found in HRT nonusers (ORlog2 [95% CI]: 1.14 [0.80-1.62], p = 0.48). Further, a nonsignificant inverse association was found in women with body mass indices (BMI) < 25 kg/m(2) (ORlog2 [95% CI]: 0.83 [0.67-1.03], p = 0.09), as opposed to a borderline significant positive association in women with BMI ≥ 25 kg/m(2) (ORlog2 [95% CI]: 1.30 [1.0-1.69], p = 0.05). Overall, prediagnostic levels of circulating 25(OH)D were not related to the risk of breast cancer in the EPIC study. This result is in line with findings in the majority of prospective studies and does not support a role of vitamin D in the development of breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 27% |
| Student > Bachelor | 8 | 11% |
| Student > Ph. D. Student | 7 | 9% |
| Student > Master | 5 | 7% |
| Professor | 5 | 7% |
| Other | 11 | 15% |
| Unknown | 18 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 38% |
| Nursing and Health Professions | 9 | 12% |
| Agricultural and Biological Sciences | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Other | 2 | 3% |
| Unknown | 19 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2013.
All research outputs
#22,012,573
of 24,558,777 outputs
Outputs from International Journal of Cancer
#11,421
of 12,088 outputs
Outputs of similar age
#175,631
of 200,428 outputs
Outputs of similar age from International Journal of Cancer
#69
of 72 outputs
Altmetric has tracked 24,558,777 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,088 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,428 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.